COVID-19 – Biofortis’ Continuity Plan

Posted On 2020-05-25

Biofortis, covid19

UPDATE – May 25th of 2020

At Biofortis Mérieux NutriSciences, we have been monitoring the COVID-19 issue closely and we will continue to do so. Our main objective is not to spread the virus within our offices and to help fight the pandemic outside.

Now that the lockdown is over, Biofortis has taken all the necessary steps to enable all of our staff, except teleworkers, to come back safely on site and return to our regular activity. Today, our doors are open: we can ensure all of our services and  welcome volunteers to continue your projects again. Our main priority is to guarantee the safety of our employees and volunteers while serving our customers with no compromises on service quality. 

In addition of our standard services, clinical trial, central lab, microbiome, data analytics, and according the roots of our company, Biofortis supports the french COVID-19 testing program with two new services in response to the health challenges of COVID-19: 

  • in vitro Diagnostics / as part of the national effort to deploy diagnostic tests, Biofortis has received an agreement to offer its analytical capacity to medical biology laboratories in order to meet the need for coronavirus test-detection of the SARS-CoV-2 genome by RT PCR

  • Surface testing / in support of MXNS laboratories by giving access to some of our facilities and equipment: same molecular test but validated for industrial and hospital surfaces

Detection of the SARS-CoV-2 genome by RT PCR

We come in support of the medical laboratory to offer our services in order to respond to a public health issue. Indeed, as a central lab for clinical studies, we are used to working on germs, including some dangerous bacteria. Thus, we already have completely secure procedures and premises in place. This type of public health mission therefore makes sense for Biofortis. Today, before putting these analyses into practice, several validations have to be carried out (analytical and organisational in particular). To ensure the safety of our employees and volunteers, Biofortis will receive only samples in its laboratory to conduct the analytical part of the diagnosis: the 1st stage of nasopharyngeal sampling and the last stage of biological validation will be carried out by medical laboratories. 

Here is a link towards an article written by Thomas Carton one month ago, about the detection method of coronavirus if you want to know more: About Coronavirus detection methods

Don’t hesitate to contact us for more information: biofortis-contact@mxns.com

covid19 biofortis

Related Posts

[NEWS] Welcome aboard Morgan and Fanny!

[NEWS] Welcome aboard Morgan and Fanny!

We are pleased to welcome Morgan Cabigliera, as Head of the Sales & Marketing Business Unit and Fanny Doistau, as Clinical Business Unit Director, as part of the Biofortis team.  Morgan has a...